摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-1-(4-phenylbut-2-en-1-yl)piperazine | 1535200-80-6

中文名称
——
中文别名
——
英文名称
(Z)-1-(4-phenylbut-2-en-1-yl)piperazine
英文别名
1-[(Z)-4-phenylbut-2-enyl]piperazine
(Z)-1-(4-phenylbut-2-en-1-yl)piperazine化学式
CAS
1535200-80-6
化学式
C14H20N2
mdl
——
分子量
216.326
InChiKey
PCMKWHGDHQPFGP-PLNGDYQASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (Z)-1-(4-phenylbut-2-en-1-yl)piperazineN-Boc-2,6-二甲基-L-酪氨酸N,N-二异丙基乙胺6-氯-1-羟基苯并三氮唑三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 生成 (S,Z)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(4-phenylbut-2-en-1-yl)piperazin-1-yl)propan-1-one
    参考文献:
    名称:
    Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
    摘要:
    In this letter, we describe a series of 4-substituted piperidine and piperazine compounds based on tetrahydroquinoline 1, a compound that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR). We have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree. Furthermore, several of the compounds described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism. The MOR agonist/DOR antagonist has shown promise in the reduction of negative side effects displayed by selective MOR agonists, namely the development of dependence and tolerance. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.12.021
  • 作为产物:
    描述:
    苯乙醛 在 sodium hydride 、 二异丁基氢化铝三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 18.92h, 生成 (Z)-1-(4-phenylbut-2-en-1-yl)piperazine
    参考文献:
    名称:
    Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
    摘要:
    In this letter, we describe a series of 4-substituted piperidine and piperazine compounds based on tetrahydroquinoline 1, a compound that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR). We have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree. Furthermore, several of the compounds described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism. The MOR agonist/DOR antagonist has shown promise in the reduction of negative side effects displayed by selective MOR agonists, namely the development of dependence and tolerance. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.12.021
点击查看最新优质反应信息

文献信息

  • Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
    作者:Aaron M. Bender、Mary J. Clark、Michael P. Agius、John R. Traynor、Henry I. Mosberg
    DOI:10.1016/j.bmcl.2013.12.021
    日期:2014.1
    In this letter, we describe a series of 4-substituted piperidine and piperazine compounds based on tetrahydroquinoline 1, a compound that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR). We have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree. Furthermore, several of the compounds described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism. The MOR agonist/DOR antagonist has shown promise in the reduction of negative side effects displayed by selective MOR agonists, namely the development of dependence and tolerance. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多